News

31. Isis Initiates Phase 2 Study Of ISIS-APOCIIIRx In Patients With Hypertriglyceridemia 5/4/2012

    Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia. Hypertriglyceridemia, a condition characterized by high levels of triglycerides, is often associated with premature coronary artery disease and pancreatitis.

32. Prana Enrolls First Patient In The 'Reach2HD' Phase II Huntington Disease Trial 4/30/2012

    Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that the first patient has been dosed in the "Reach2HD Trial" - a 6 month Phase IIa clinical trial testing PBT2, the Company's drug in development for Huntington disease

33. AstraZeneca To Acquire Ardea Biosciences For $1.26B Including Lead Product Lesinurad In Phase III Development For Gout 4/23/2012

    AstraZeneca and Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.

34. Sanofi And Michael J. Fox Foundation Collaborate On Potential New Treatment For Parkinson's Disease 4/19/2012

     Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi PDE4 inhibitor – phosphodiesterase type 4 inhibitor - in patients with Parkinson's disease (PD).

35. InspireMD Announces Continued Progress In MASTER Trial 4/16/2012

    InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, today announced that the 313th patient has been enrolled in the MASTER (MGuard™ for Acute ST Elevation Reperfusion) trial. The trial is scheduled to enroll 432 patients in total and the Company is on track to release preliminary top line results in the third quarter of 2012

36. Threshold Pharmaceuticals Earns $20M Milestone Payment From Merck KGaA For Positive Results From Phase 2 Trial Of TH-302 In Pancreatic Cancer 4/12/2012

    Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced it has earned a $20 million milestone payment from Merck KGaA, Darmstadt, Germany, for achieving a statistically significant progression free survival benefit in its 214-patient randomized controlled Phase 2 clinical trial ("404 trial") evaluating the efficacy and safety of two doses of TH-302, a hypoxia-targeted drug, in combination with gemcitabine compared to gemcitabine alone in patients with first-line advanced pancreatic cancer.

37. Peregrine Launches PS-Targeting Clinical Imaging Program 4/4/2012
    Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that it has launched a program for its experimental phosphatidylserine (PS)-targeting molecular imaging candidate, ¹²⁴I-PGN650, for the imaging of multiple solid tumor types.
38. Many Cancer Rates Continue To Decline 4/2/2012
    Death rates from all cancers combined for men, women, and children continued to decrease in the United States between 2004 and 2008.
39. Sanofi And Regeneron Report Phase 2 Data For Potential First-In-Class Lipid-Lowering PCSK9 Antibody 3/29/2012

    Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.

40. Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol Up To 81 Percent In Phase 1b Study 3/26/2012
    Amgen (NASDAQ: AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins.